Podcast: Immune Persistence After Primary Vaccination with MenQuadfi
Mika Rämet, Mike Simon · 2026
Read Podcast: Immune Persistence After Primary Vaccination with MenQuadfi by Mika Rämet, Mike Simon (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13350569.txt.
Description
Mika Rämet and Mike Simon discussed in 2026 immune persistence after primary vaccination with MenQuadfi, a quadrivalent meningococcal conjugate vaccine, in a podcast-format review. Invasive meningococcal disease is rare but progresses fast, killing ten to fifteen percent of patients and leaving survivors with hearing loss, nerve harm, or limb loss.
Disease load and serogroups vary by region. The African meningitis belt past faced serogroup A, with C, W, and X rising lately, while Europe sees mostly B in infants and teens and rising Y in older adults. Polysaccharide vaccines helped curb outbreaks but give limited durability. The discussion weighs how long MenQuadfi guard lasts and how region-specific rules should time boosters.
Catalog record
| CREATOR | Mika Rämet, Mike Simon |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |